Date: 2022-01-28
Type of information: Construction of new premises
Compound: new fill finish site in Morocco
Company: Recipharm (Sweden)
Therapeutic area:
Type agreement:
Action mechanism:
Disease:
Details: Recipharm, in charge, together with the Moroccan government, of shaping the new entity SENSYO Pharmatech, has attended a ceremony to recognise the launch of construction works of the new fill finish site. This is a major investment in the site by the Moroccan Government, a consortium of the country's leading banks and Recipharm over the next five years to establish both capacity and capability for Morocco to manufacture vaccines and biotherapeutics in the Kingdom. The investment is another step towards effective management of the pandemic and will contribute to ensuring vaccine self-sufficiency for the Kingdom and supply to the African continent as a whole.
The facility, named SENSYO Pharmatech, is in line with His Majesty's vision to position Morocco as a key biotechnology hub that is capable of meeting the short and long-term health needs of people across Africa by integrating pharmaceutical research, clinical development, manufacturing and marketing of pharmaceutical products. SENSYO Pharmatech aims to be the largest fill and finish platform in Africa. It will focus on the fill finish of vaccines and will feature three industrial lines which are forecast to produce more than 100 million units in 2024. These lines will be dedicated to producing vials and vaccines in syringes. It is being constructed on a 30 hectare greenfield site and is expected to be operational by 2023.
Between 2022-2025, the aim is the fill finish (bulk manufacturing is off scope of SENSYO Pharmatech) of more than 20 vaccines and bio-therapeutic products, including three Covid-19 vaccines to meet the needs of people in Morocco and Africa.
Financial terms:
Latest news:
